Global Gastrointestinal Therapeutics and Diagnostics

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 17, 2017 at 12:00 PM 68

Global Gastrointestinal Therapeutics and Diagnostics Technologies and Markets Report 2016-2021

Dublin, April 17, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report to their offering. The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015. This market is expected to grow from nearly $51.8 billion in 2016 to $63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-2021. This report is designed to provide an in-depth look at the therapeutic and diagnostic options of various gastrointestinal disorders. The geographic scope of the report is global, with particular emphasis on the key markets such as the U.S. and the European Union Five (EU5). The estimated market data is also global in nature, with geographic segments such as the U.S., EU and Rest of the World (ROW). The report provides a brief overview of the gastrointestinal system, which provides an introduction to the disorders of the gastrointestinal system; cites risk factors, where applicable; presents current pharmaceutical treatments, market size and key market participants (both prescription and OTC); and presents potential treatments in R&D, potential market size and future market entrants.

This report provides: - An overview of the global markets for gastrointestinal therapeutics and diagnostics. - Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021. - Analyses of therapeutics currently on the market as well as potential products and classes of products that are likely to have a significant impact. - Descriptions of the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future. - Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities. - Profiles of major players in the industry. The market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments: - Diagnostics and testing market. - Medical devices (endoscopy) - Vaccines. The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following: - Gastrointestinal tract disorders. - Gastrointestinal tract walls disorders. - Gastrointestinal motility disorders. - Gastrointestinal cancers. Each sub-segment is covered in detail, describing the disorders and diseases, identifying currently available and potential products, and competitors. Key Topics Covered: 1: Introduction Complimentary - Study Goals And Objectives - Reasons For Doing The Study - Intended Audience - Scope Of Report - Methodology And Information Sources 2: Executive Summary - Gastrointestinal Therapeutics And Diagnostics 3: Overview - Gastric Cancer - Inflammatory Bowel Disease (IBD) - Constipation - Opioid-Induced Constipation - Gastroesophageal Reflux Disease 4: Etiology - Anatomy And Physiology Of The Gastrointestinal System - The Enteric Nervous System: An Overview - Factors Affecting The Functioning Of The GI System - Physiology Of The Gi System And The Role Of Each Part In The Gi Process 5: Prescription Therapy Market - Antidiarrheals - Antiemetics - Gastrointestinal Cancer Treatments - Gastroesophageal Reflux Disease Treatments - Proton Pump Inhibitors - Laxatives - Bowel Anti-Inflammatory - Other GI Drugs 6: OTC Therapy Market - Antacids - Locally Acting Antidiarrheals - H2 Inhibitors - Proton Pump Inhibitors - Laxatives - Total OTC Gastrointestinal Drug Market Size And Growth 7: Diagnostics And Devices Market - Enteric Disease Testing Methods - Global Market For Enteric Diagnostic Tests - Campylobacter - Norovirus - Rotavirus - Giardia Parasite - E. Coli - Cryptosporidium - Shigella - Typhoid - Amebiasis - Cholera - Other (H. Pylori, Yersinia) Diagnostic Tests - Medical Devices (Endoscopy) 8: Gastrointestinal Product Pipeline - Therapies For Treating Gastric Cancer - Gerd And Peptic Ulcers - Therapies For Treating IBS - Therapies For Treating Ulcerative Colitis And Crohn'S Disease 9: Patents 10: Company Profiles - Allergan Plc - Ardelyx Inc. - Astellas Pharma Inc. - Astrazeneca - Celgene Corp. - Clovis Oncology - Daewoong Pharmaceutical Co., Ltd. - ELI Lilly And Company - Glaxosmithkline - Horizon Pharma Plc - Immunogenx - Immunomedics - Merck & Co. - Merrimack Pharmaceuticals Inc. - New Link Genetics - Otsuka Holdings Co. Ltd. - Pfizer Inc. - Roche - Sanofi - Shire - Sucampo Pharmaceuticals Inc. - Synergy Pharmaceuticals Inc. - Synthetic Biologics - Taiho Pharmaceutical Co., Ltd. - Takeda Pharmaceuticals - Valeant Pharmaceuticals For more information about this report visit http://www.researchandmarkets.com/research/wq...intestinal

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Diagnostics, Gastrointestinal Drugs

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

CVS Study: GLP-1 Drugs Effective But Costly

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...